PHARMACEUTICAL INTERMEDIATES PROPOSED FOR DUTY ELIMINATION—Continued

IUPAC Name	CAS No.
2,6-dichloro-4-methylnicotinonitrile	875–35–4
3,5-diacetamido-2,4,6-triiodobenzoic acid dihydrate	50978-11-5
2,2,2-trifluoroethanol	75–89–8
13-ethyl-17-alpha-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one oxime	53016-31-2
Estropipate	7280-37-7
4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide	180200-68-4
17-alpha-hydroxy-3,20-dioxopregna-4,9(11)-diene-21-yl acetate	7753-60-8
Hemocyanins, megathura crenulata, reaction products with 1-O-[O-2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1,4)-O-(N-	
acetyl-alpha-neuraminosyl)-(2,3)]-O-beta-D-galactopyranosyl-(1,4)-beta-D-glucopyranose	195993-11-4
1-(28-{O-D-apio-beta-D-furanosyl-(1,3)-O-beta-D-xylopyranosyl-(1,4)O-6-deoxy-alpha-L-mannopyranosyl)-(1,2)-4-O-[5-(5-alpha-	
L-arabinofuranosyloxy-3-hydroxy-6-methyloctanoyloxy)-3-hydroxy-6-methyloctanoyl]-6-deoxy-beta-D-galactopyranosyloxy}-16-	
alpha-hydr ox	141256-04-4
1-O-[O-(N-acetyl-alpha-neuraminosyl)-(2,3)-O-[O-beta-D-galactopyranosyl-(1,3)-2-acetamido-2-deoxy-beta-D-galactopyranosyl-	
(1,4)I-O-beta-D-galactopyranosyl-(1,4)-beta-D-glucopyra nosyllceramide	104443-62-1
1-O-[O-2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1,4)-O-(N-acetyl-alpha-neuraminosyl)-(2,3)-O-beta-D-galactopyranosyl-	
(1,4)-beta-D-glucopyranosyl]ceramide	104443-57-4
N-{[(1R,2R)-1- O-(N-acetyl-alpha-neuraminosyl)-(2,3)-O-2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1,4)-O-beta-D-	
galactopyranosyl-(1,4)-beta-D-glucopyranosyloxymethyl]-2-hydroxy-3-formylpropyl}stearamide	196085-62-8
Ferristene	155773-56-1
Codeine phosphate hemihydrate	41444-62-6
Trans-1-benzoyl-4-phenyl-L-proline	120851-71-0
5-methyluridine hemihydrate	25954–21–6
5'-benzoyl-2',3'-didehydro-3'-deoxythymidine	122567-97-9
3′,5′-anhydrothymidine	38313-48-3
4'-(benzyloxycarbonyl)-4'-demethylepipodophyllotoxin	23363-33-9
2,3,4,6-tetra-O-benzyl-1-O-(trimethylsilyl)-b-D-glucose	80312–55–6
2,3,4,6-tetra-O-benzyl-D-glucose	4132-28-9
6-iodo-1H-purin-2-ylamine	19690-23-4
(1R,2R,3S)-2-amino-9-[2,3-bis(benzoyloxymethyl)cyclobutyl]-9H-purin-6-one	156126-53-3
(1RS,2RS,3SR)-2,3-bis(benzoyloxymethyl)cyclobutylamine	151807-53-3
(1RS,2RS,3RS)-2,3-bis(benzoyloxymethyl)cyclobutanol	127759-90-4
(1R,2R,3S)-9-[2,3-bis(benzoyloxymethyl)cyclobutyl]-6-iodo-9H-purin-2-ylamine	156126-89-3
(2S,3S)-2,3-bis(benzoyloxymethyl)cyclobutanone	132294-16-7
(S)-5-(1,3-dioxolan-4-yl)-2-aminovaleric acid	170242-34-9
N,N'-bis(trifluoroacetyl)-DL-homocystine	105996-54-1
(S)-2-(acetylthio)-3-phenylpropionic acid—dicyclohexylamine (1:1)	157521-26-1
Methyl (4S.7S.10aS)-4-amino-5-oxooctahydro-7H-pyrido[2.1-b][1.3]thiazepine-7-carboxylate	167304-98-5
4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-ylmethyl)biphenyl-2-carbonitrile	138401-24-6
DL-5-(1,2-dithiolan-3-yl)valeramide	3206-73-3
4-(4-methoxyphenyl)butan-2-one	104–20–1
Tetraisopropyl methylenediphosphonate	1660–95–3
(S)-1,2,3,4-tetrahydroisoguinoline-3-carboxylic acid	74163–81–8
(S)-N-tert-butyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride	149057-17-0
(S)-N-tert-butyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide sulfate	186537-30-4
(3S)-tetrahydrofuran-3-yl (1S,2R)-3-[(4-aminophenylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate	161814–49–9
6-benzyl-1-(ethoxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione	149950-60-7
(2R,5S)-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one	143491-57-0
3'-azido-2',3'-dideoxy-5-methylcytidine hydrochloride	108895-45-0
(2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1,3-dioxolan-2-ylmethanol	145514-04-1
(4R,5S,6S,7R)-1,3-bis(3-aminobenzyl)-4,7-dibenzyl-5,6-dihydroxyhexahydro-2H–1,3-diazepin-2-one dimethanesulfonate	177932-89-7
(Tr., 50, 50, 717) 1,5 015(5 annihobenzyl)-4,7 -albenzyl-5,0-allyaroxyriexanyaro-zi i=1,5-alazepin-z-one allinethaliesallonate	171932-09-1

[FR Doc. 99–1342 Filed 1–20–99; 8:45 am] BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-413]

Certain Rare Earth Magnets and Materials and Articles Containing Same; Notice of Commission Determination Not To Review an Initial Determination Amending the Complaint and the Commission's Notice of Investigation To Add Four Respondents

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination (ID) issued by the presiding administrative law judge (ALJ) in the above-captioned investigation. The ALJ granted the motion of complainants Magnequench International, Inc. (Magnequench) and Sumitomo Special Metals Co. Ltd. (SSMC) to add four respondents to the investigation.

ADDRESSES: Copies of the nonconfidential version of the ID and all other non-confidential documents filed in connection with this investigation are available for inspection during official

business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205–2000.

FOR FURTHER INFORMATION CONTACT: Jean Jackson, Esq., Office of the General Counsel, U.S. International Trade Commission, telephone 202–205–3104. Hearing-impaired individuals are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on 202–205–1810. General information concerning the Commission may also be obtained by accessing its Internet server (http://www.usitc.gov).

SUPPLEMENTARY INFORMATION: On September 4, 1998, the Commission instituted an investigation based on a complaint filed by Magnequench International, Inc. (Magnequench) and Sumitomo Special Metals Co. (Sumitomo) of Japan alleging violations of section 337 of the Tariff Act of 1930 in the importation and sale of certain rare-earth magnets and magnetic materials and articles containing the same by reason of infringement of several claims of six U.S. patents, three of which are held by Magnequench and three of which are held by Sumitomo. 63 FR 47319. Eight firms were named as respondents.

On November 18, 1998, Magnequench and Sumitomo filed a motion to amend the complaint and the notice of investigation to add (1) A.R.E., Inc. of 777 Linden St. or 782 Pearl St., Sharon, PA 16146; (2) NEOCO, L.C. of 777 Linden St., Sharon, PA or 3128 Walton Blvd., Suite 197, Rochester Hills, MI 48309; (3) Beijing Jing Ma Permanent Magnetic Factory West Building Number 8, Chaoyang District, Beijing, China; and (4) Xin Huan Technology Development Co., Ltd., No. 8 South 3rd St., Zhong Guan Cun Road, Beijing, China as respondents to the investigation. On December 10, 1998, the ALJ granted complainants' motion, finding that the complainants had demonstrated good cause for adding the named respondents at this time. No petitions for review were filed.

This action is taken under the authority of section 337 of the Tariff Act of 1930 (19 U.S.C. § 1337) and section 210.42(h) of the Commission's Rules of Practice and Procedure (19 C.F.R. § 210.42(h)).

Issued: January 11, 1999. By order of the Commission.

Donna R. Koehnke,

Secretary

[FR Doc. 99–1349 Filed 1–20–99; 8:45 am] BILLING CODE 7020–02–P

DEPARTMENT OF LABOR

Pension and Welfare Benefits Administration

[Prohibited Transaction Exemption 99–01; Exemption Application No. D–10535, et al.]

Grant of Individual Exemptions; Moody-Day, Inc. Profit Sharing Plan, et al

AGENCY: Pension and Welfare Benefits Administration. Labor.

ACTION: Grant of individual exemptions.

SUMMARY: This document contains exemptions issued by the Department of Labor (the Department) from certain of the prohibited transaction restrictions of the Employee Retirement Income Security Act of 1974 (the Act) and/or the Internal Revenue Code of 1986 (the Code).

Notices were published in the **Federal Register** of the pendency before the Department of proposals to grant such exemptions. The notices set forth a summary of facts and representations contained in each application for exemption and referred interested persons to the respective applications for a complete statement of the facts and representations. The applications have been available for public inspection at the Department in Washington, D.C. The notices also invited interested persons to submit comments on the requested exemptions to the Department. In addition the notices stated that any interested person might submit a written request that a public hearing be held (where appropriate). The applicants have represented that they have complied with the requirements of the notification to interested persons. No public comments and no requests for a hearing, unless otherwise stated, were received by the Department.

The notices of proposed exemption were issued and the exemptions are being granted solely by the Department because, effective December 31, 1978, section 102 of Reorganization Plan No. 4 of 1978 (43 FR 47713, October 17, 1978) transferred the authority of the Secretary of the Treasury to issue exemptions of the type proposed to the Secretary of Labor.

Statutory Findings

In accordance with section 408(a) of the Act and/or section 4975(c)(2) of the Code and the procedures set forth in 29 CFR Part 2570, Subpart B (55 FR 32836, 32847, August 10, 1990) and based upon the entire record, the Department makes the following findings:

(a) The exemptions are administratively feasible;

- (b) They are in the interests of the plans and their participants and beneficiaries; and
- (c) They are protective of the rights of the participants and beneficiaries of the plans.

Moody-Day, Inc. Profit Sharing Plan (the Plan); Located in Carrollton, Texas; Exemption

[Prohibited Transaction Exemption 99–01; Exemption Application No. D–10535]

The restrictions of sections 406(a), 406(b)(1) and (b)(2) of the Act and the sanctions resulting from the application of section 4975 of the Code, by reason of section 4975(c)(1)(A) through (E) of the Code, shall not apply to the past sale (the Sale) by the Plan of an unimproved three-acre tract of real property located in Austin, Texas (the Property) to Metroport Realty Corporation, an affiliate of Moody-Day, Inc., the Plan sponsor and a party in interest with respect to the Plan, provided the following conditions were satisfied:

- (A) the Sale was a one-time transaction for cash:
- (B) the Plan received the fair market value of the Property on the date of the Sale;
- (C) the Property was appraised by qualified, independent real estate appraisers;
- (D) a qualified, independent fiduciary determined that the Sale was in the best interests of the Plan; and
- (E) the Plan paid no commissions or other expenses relating to the Sale.

For a more complete statement of the facts and representations supporting the Department's decision to grant this exemption, refer to the Notice of Proposed Exemption published on November 9, 1998 at 63 FR 60386.

EFFECTIVE DATE: This exemption has an effective date of May 24, 1995.

FOR FURTHER INFORMATION CONTACT: Janet L. Schmidt of the Department, telephone (202) 219–8883. (This is not a toll-free number.)

Toledo Clinic, Inc. Employees 401(k) and Profit Sharing Plan (the T/C Plan); Hart Associates, Inc. Profit Sharing Plan (the H/A Plan); and Midwest Fluid Power Company, Inc. Savings and Profit Sharing Plan and Trust (the M/F Plan, Collectively; the Plans) Located in Toledo, Ohio; Exemption

[Prohibited Transaction Exemption 99–02; Exemption Application Nos. D–10633, D– 10634 and D–10635, respectively]

The restrictions of sections 406(a), 406(b)(1) and (b)(2) of the Act and the sanctions resulting from the application of section 4975 of the Code, by reason of section 4975(c)(1)(A) through (E) of